200 related articles for article (PubMed ID: 26381660)
21. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
Aghamohammadi A; Hosseinimehr SJ
Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
[TBL] [Abstract][Full Text] [Related]
23. [Endoglin (CD105)--a target for visualization and anti-angiogenic therapy for malignant tumors].
Smirnov IV; Gryazeva IV; Samoilovich MP; Klimovich VB
Vopr Onkol; 2015; 61(6):898-907. PubMed ID: 26995976
[TBL] [Abstract][Full Text] [Related]
24. [Angiogenesis as part of the tumor "ecosystem" and possibilities to influence it].
Klener P
Klin Onkol; 2010; 23(1):14-20. PubMed ID: 20192069
[TBL] [Abstract][Full Text] [Related]
25. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.
Aalders KC; Tryfonidis K; Senkus E; Cardoso F
Cancer Treat Rev; 2017 Feb; 53():98-110. PubMed ID: 28088074
[TBL] [Abstract][Full Text] [Related]
26. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
Giraudo E; Inoue M; Hanahan D
J Clin Invest; 2004 Sep; 114(5):623-33. PubMed ID: 15343380
[TBL] [Abstract][Full Text] [Related]
27. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
[TBL] [Abstract][Full Text] [Related]
28. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
29. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor and bevacitumab in breast cancer.
Bando H
Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
Gadducci A; Lanfredini N; Sergiampietri C
Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis as a target for breast cancer therapy.
Rayson D; Vantyghem SA; Chambers AF
J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):415-23. PubMed ID: 10705924
[TBL] [Abstract][Full Text] [Related]
35. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
36. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
37. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
Labanca V; Bertolini F
EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
[No Abstract] [Full Text] [Related]
38. [Molecular targeting therapy for gynecologic cancer].
Nakayama K; Miyazaki K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():524-8. PubMed ID: 23513895
[No Abstract] [Full Text] [Related]
39. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
40. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
